Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

News

News
10/06/2022
The uptake of targeted oral anticancer medicines expanded from 3.6% to 8.9% in a study population between 2011 to 2016, according to a recent study.
The uptake of targeted oral anticancer medicines expanded from 3.6% to 8.9% in a study population between 2011 to 2016, according to a recent study.
The uptake of targeted oral...
10/06/2022
Journal of Clinical Pathways
News
09/27/2022
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
News
09/22/2022
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study...
09/22/2022
Journal of Clinical Pathways
News
09/20/2022
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022
Among patients with CLL with disease progression who were treated with ibrutinib, overall survival was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy or venetoclax-based treatment compared to other...
Among patients with CLL with disease progression who were treated with ibrutinib, overall survival was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy or venetoclax-based treatment compared to other...
Among patients with CLL with...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways
News
09/20/2022
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume...
09/20/2022
Oncology
News
09/19/2022
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
News
09/13/2022
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on...
09/13/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement